拜瑞妥是治疗什么的？

(Rivaroxaban) is a red film-coated tablet that is a highly selective oral drug that directly inhibits factor Xa. By inhibiting factor Xa, it can interrupt the endogenous and exogenous pathways of the coagulation waterfall and inhibit thrombin generation and thrombosis. Today let’s take a closer look at what Xarelto treats?

Indications of Xarelto (rivaroxaban): 1. For the prevention of venous thrombosis (VTE) in adult patients undergoing elective hip or knee replacement surgery. 2. Used to treat venous thrombosis (DVT) in adults and reduce the risk of DVT recurrence and pulmonary embolism (PE) after acute DVT. 3. For use in adult patients with non-valvular atrial fibrillation who have one or more risk factors (such as congestive heart failure, hypertension, age ≥75 years, diabetes, history of stroke or transient ischemic attack) to reduce the risk of stroke and systemic embolism.

Dosage and usage of Xarelto (rivaroxaban): The recommended dose is 10 mg of Xarelto taken orally, once daily. If the wound has stopped bleeding, the medication should be administered between 6-10 hours after surgery. The length of treatment is determined by each patient's risk of VTE, i.e. by the type of orthopedic surgery the patient has undergone. For patients undergoing major hip surgery, a recommended course of treatment is 5 weeks. For patients undergoing major knee surgery, a recommended course of treatment is 2 weeks. If a dose is missed, the patient should take Xarelto immediately and continue taking the medication once a day the next day. Patients can take Xarelto with a meal or alone.

Xarelto (rivaroxaban) received marketing approval in Canada and the European Union on September 15 and October 1, 2008, respectively. On July 1, 2011, the FDA approved the drug for the prevention of deep vein thrombosis in patients undergoing knee or hip replacement surgery. It was approved for marketing by the State Food and Drug Administration in March 2009, and was successfully included in the 2009 National Medical Insurance Catalog in the same year.

In addition, things to note about Xarelto (rivaroxaban) are: 1. Patients with liver and renal insufficiency can significantly increase the blood concentration of this product, leading to an increased risk of bleeding. 2. Patients with active bleeding; patients with liver disease who have coagulation abnormalities and clinically relevant bleeding risks; 3. Contraindicated in pregnant and lactating women. 

  The above is the indications of (Rivaroxaban), I hope it can help you!

Recommended related hot articles: /newsDetail/76622.html